A KRAS biotech from Bert Vogelstein and Catalio targets $153M

A new immunotherapy biotech from famed Johns Hopkins oncology researchers Bert Vogelstein and Drew Pardoll is in the works, with a sizable $153 million financing round underway.

Vogelstein, who has founded cancer detection companies like Thrive and Haystack Oncology, has been working on a “multi-year collaboration” with Pardoll to…
Click here to view original post